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Abstract
Abetalipoproteinemia (ABL) is a rare recessive condition caused by biallelic loss-of-function mutations in the MTTP gene
encoding the microsomal triglyceride transfer protein large subunit. ABL is characterized by absence of apolipoprotein
B–containing lipoproteins and deficiencies in fat-soluble vitamins leading to multisystem involvement of which neurological
complications are the most serious. We present 3 siblings with ABL who were born to non-consanguineous parents of
Filipino and Chinese background. Identical twin boys with long-standing failure to thrive and malabsorption were diagnosed
at age 2 years. ABL therapy with vitamins and a specialized diet was initiated, replacing total parenteral nutrition at age 3
years. Their younger sister was diagnosed from a blood sample taken at birth; treatment was instituted shortly thereafter.
We observed in the twins reversal and in their sister prevention of ABL systemic features following early implementation
of fat restriction and high doses of oral fat-soluble vitamins. A targeted sequencing panel found that each affected sibling is
homozygous for a novel MTTP intron 13 -2A>G splice acceptor site mutation, predicted to abolish splicing of intron 13. This
variant brings to more than 60 the number of reported pathogenic mutations, which are summarized in this article. The twin
boys and their sister are now doing well at 11 and 4 years of age, respectively. This experience underscores the importance
of early initiation of targeted specialized dietary and fat-soluble vitamin replacements in ABL.
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Introduction
Abetalipoproteinemia (ABL; OMIM 200100) is an autosomal recessive disorder whose core biochemical defect is
impaired absorption of dietary lipids with impaired assembly and secretion of apolipoprotein (apo) B–containing
lipoprotein particles.1 Biallelic pathogenic mutations have
been reported in all functional domains of the MTTP gene
that encodes the microsomal triglyceride (TG) transfer
protein large subunit (MTP) in ABL patients.2 MTP plays a
critical role in the assembly of lipoproteins. In the intestine
and liver MTP transfers lipid to apo B-48 and apo B-100,
respectively, to form chylomicrons and very-low-density
lipoprotein (VLDL), respectively (Figure 1).3 The impaired
VLDL secretion results in severe reduction of its remodeled end product in plasma, namely, low-density lipoprotein (LDL).4 The absence of functional MTP in ABL
manifests as extremely low to undetectable levels of apo
B–containing lipoproteins, total and LDL cholesterol, TG,
and of plasma biomarkers reflecting the status of vitamins
A, D, E, and K.5

ABL patients typically present in early childhood with
failure to thrive and steatorrhea.1 Chronic vitamin deficiencies produce serious physiologic and developmental consequences, including retinal degeneration from vitamin A
deficiency, osteomalacia and osteoporosis from vitamin D
deficiency, and prolonged international normalized ratio
from vitamin K deficiency.1 Chronic vitamin E deficiency
results in severe, progressive neuromuscular deficits.1
Individuals with untreated ABL typically develop muscle
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Figure 1. Microsomal triglyceride (TG) transfer protein (MTP)
and lipoprotein assembly. Fatty acids (FA) in the intestine or
liver are assembled into TG by diacylglycerol acyltransferases.
In enterocytes, MTP combines TG, cholesterol, phospholipids,
dietary fat–soluble vitamins with the B-48 intestine-specific
isoform of apolipoprotein (apo) B to form chylomicrons that
enter the plasma through intestinal lymphatics and are catabolized
to remnant particles by lipoprotein lipase. MTP activity in
hepatocytes is similar except the liver-specific B-100 isoform is
incorporated into very-low-density lipoprotein (VLDL) particles,
which are catabolized to intermediate-density lipoprotein
(IDL) and ultimately low-density lipoprotein (LDL) particles
by plasma lipases. LDL is removed from plasma by hepatic
LDL receptors. Biallelic mutations that abolish MTP activity in
abetalipoproteinemia result in complete absence of the above
apo B–containing lipoproteins. The associated deficiency of fatsoluble vitamins occurs because chylomicrons are unavailable to
transport them.

weakness, dysarthria, and a loss of deep tendon reflexes,
vibratory sense, and proprioception in childhood, and which
later progresses to Friedreich’s-like spinocerebellar
ataxia.1,5,6 Mild hemolytic anemia develops secondary to
acanthocytosis. The differential diagnosis of ABL includes
homozygous hypobetalipoproteinemia1,5 and chylomicron
retention disease7 due to biallelic rare mutations in the APOB
and SAR1B genes, respectively. These conditions can be differentiated from ABL using both biochemical analyses and
diagnostic DNA sequencing.8
Treatment of ABL involves the following: (1) dietary
restriction of fats to improve malabsorption symptoms and
(2) supplementation with high-dose oral fat-soluble vitamins
to avert complications.5 Delayed diagnosis and treatment of
ABL results in delayed growth and development along with
irreversible ophthalmologic and neurologic complications.5,6
We present a unique Filipino/Chinese Canadian family with
3 siblings—identical twin boys and their sister—who were
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Figure 2. (A) Pedigree of abetalipoproteinemia (ABL) family.
The parents are each carriers of one copy of the same mutant
allele (MTTP intron 13 -2A>G). Their children, identical twin
boys, and their younger sister are homozygous for this mutant
allele. (B) Growth trajectories of the 3 siblings affected by ABL.
Siblings are identified as indicated and are described clinically in
the text.

born to non-consanguineous parents and were diagnosed
with ABL. Each was homozygous for a previously unreported rare MTTP intron 13 -2A>G variant, which was predicted to abolish normal RNA splicing. Treatment for the
boys was started at age 3 years and for their younger sister
was started shortly after birth, with successful long-term outcomes to date.

Subjects and Methods
Probands
Identical 3-year-old twin boys of East and South East Asian
ancestry were referred to our lipid clinic with a history of
failure to thrive and steatorrhea from shortly after birth
(Figure 2A). A clinical diagnosis of ABL was made at age 18
months at another center and total parenteral nutrition (TPN)
was subsequently initiated. There were no specific restrictions on oral intake. At the time of presentation to our clinic,
the twins were severely underweight with reduced appetite
(Figure 2B), low energy, easy fatigability, and significant
muscle weakness along with developmental delay for most
milestones. There were no visual symptoms, nor was there a
history of easy bruising or bleeding. In addition, both twins
had persistent abdominal bloating and daily large volume
steatorrhea. For both twins, serum levels of vitamins A and E
were undetectable, vitamin D was at the lower limit of normal, while international normalized ratio was normal in both
at 1.1.
After assessment in our clinic, the parents were advised to
discontinue TPN and initiate a more varied diet, but with
restriction of fat to 20% of total calories. High doses of oral
vitamins were also initiated: vitamin A 20 000 IU daily,
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Figure 3. Synopsis of reported MTTP mutations causing abetalipoproteinemia. The top panel shows the functional domains of the MTP
protein, which are encoded by the indicated regions of the MTTP gene depicted with its 18 exons and 17 introns in the middle of the
figure. Point mutations, frame-shifting insertions and deletions, and splicing mutations are indicated and occur throughout the MTTP
gene, affecting all functional domains of the MTP protein. Large-scale deletions (≥25 base pairs) and MTTP mutations linked to other
conditions are not included in the figure.

vitamin D 10 000 IU 5 days per week, vitamin E 2400 U
daily, and vitamin K 5 mg per week. Within 2 months, the
parents reported that both boys were more alert, mobile, and
energetic, with reduced abdominal distension and less frequent bowel movements. Within a year, they attended preschool and thereafter primary school at a grade level
appropriate for their age, with full participation in academic
and nonacademic activities. When the twins were 9 years
old, a fatty acid supplement was added, that is, eicosapentanoic acid and docosahexanoic acid in a 1:2 ratio, for a total of
50 mg docosahexanoic acid daily.
The twin boys have remained continuously on this regimen of high-dose oral fat-soluble vitamins with dietary fat
restriction for 8 years. While they remain underweight (less
than third percentile; Figure 2B), they have regained functional strength and dexterity, and have caught up to their
peers’ developmental milestones. Their fat-soluble vitamin
plasma levels—most importantly vitamins A and E—are
now each within the detectable range, although vitamin E
levels for both are low but stable at 3 µmol/L (reference
range 18-29 µmol/L). Plasma vitamin levels are monitored
every 6 months and supplementation doses are adjusted as
required to maintain appropriate levels.5
A female full sibling was born when the twin boys were
7 years old (Figure 2A). She was diagnosed with ABL via
molecular analysis of cord blood at 3 weeks of age. She was
exclusively breast fed for the first month of life, and she
gradually transitioned to a fat-restricted diet with high-dose
medium-chain fatty acids (MCFA) and fat-soluble vitamin
supplementation by 4 months. She is developmentally

normal and has grown at or above the third percentile for
weight. Currently, she takes vitamin A 10 000 IU daily,
vitamin D 1000 IU 5 days weekly, vitamin E 1600 IU daily,
and vitamin K 2.5 mg weekly. Her most recent plasma levels of vitamins A and D are normal, while vitamin E was 3
µmol/L (reference range 18-29 µmol/L). All 3 children
undergo yearly neurological and ophthalmologic examinations as well as abdominal ultrasound examinations to
screen for hepatosteatosis; all medical monitoring has been
normal to date.

DNA Sequencing and Genetic Analysis
Each sibling provided a venous blood sample from which
genomic DNA was extracted. We used targeted next-generation pandyslipidemia sequencing panel called LipidSeq, as
described.9-13 Genotype status of the probands and parents
was confirmed by Sanger sequencing, as described.9-13

Results
Genetic Analysis
Targeted next-generation sequencing revealed in all 3 siblings a novel homozygous splicing acceptor variant that was
predicted to be deleterious; namely, MTTP c.1990 -2A>G.
Both asymptomatic parents were heterozygous for this variant. This mutation was absent from the ExAC, 1000G, and
ESP databases.14,15 The reported MTTP mutations in ABL
patients are summarized in Figure 3.
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Discussion
We present a family of East and South East Asian background with the unusual co-occurrence (1 in 64 probability)
of all 3 siblings affected with ABL. Despite no known relationship between the parents, each child was homozygous
for the identical rare unreported MTTP c.1990 -2A>G
pathogenic variant, which is predicted to have compromised
function in RNA splicing occurring within a splice acceptor
sequence in intron 13. The clinical course of these children
indicates that high-dose oral vitamin supplementation and fat
restriction can reverse the disease trajectory if initiated at 3
years of age, and can prevent systemic abnormalities when
initiated shortly after birth.
Switching the twin boys from TPN to oral diet with highdose fat-soluble vitamins resulted in generalized clinical
improvement. While TPN formulations contain lipids and
fat-soluble vitamins, the quantities are insufficient and physiologically inappropriate to affect the severe deficiencies that
are characteristic of ABL. Current treatment guidelines concur with many years of clinical experience and recommend
high oral doses of fat-soluble vitamin supplementation as a
foundation of treatment.1,5 The extent of total intestinal fat
absorption is low in ABL due to the profound defect in chylomicron synthesis. However, MCFAs can be directly
absorbed into the hepatic portal vein system, independent of
chylomicron transport1,5,6 and can provide a source of calories if clinically indicated. Furthermore, a small proportion
of high doses of orally administered vitamins A, D, E, and K
can enter the portal vein through the MCFA pathway.1,5,6
The twin boys exhibited growth and developmental
delays prior to initiation of standard treatment, but these
have reversed with treatment. Now at age 11 years, their
eating habits and bowel routine has essentially normalized.
Both are doing well in school and extracurricular activities, although they still lag behind normal trajectories for
height and weight. Their younger sister, now age 4 years,
was diagnosed days after birth and was started on fat
restriction with MCFA supplementation in the first 2
months of life, with high-dose fat-soluble vitamins initiated shortly thereafter. She maintains appropriate global
development and healthy dietary behaviors to date. The
findings here indicate that early initiation of proper lifesustaining therapy in ABL allows for ongoing appropriate
growth and development.
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